US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

710.58

+24.843.62%

Number of Gainers:84

Number of Losers:59

Number of Flat:11

PE:- -

High:710.84

Open:685.68

Low:683.13

Close:685.75

Volume:327.40M

Turnover:10.32B

Market Cap:495.36B

Float Cap:376.11B

Loading ...

Press Release: dLocal Reports Second Quarter 2026 Financial Results

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

1stDibs Executives Present at Midwest IDEAS Investor Conference

Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position

Sector Update: Financial

MT Newswires Live

Global-E CEO Amir Schlachet Sells 16,814 Shares for $713,890.60

Obsidian Therapeutics Down over 21%, on Pace for Largest Percent Decrease Since October 2024

Market Chatter: Robinhood Plans to Accelerate Debuts for Publicly Traded Closed-end Funds

MT Newswires Live

Analysts Offer Insights on Technology Companies: Riskified (RSKD) and Creative Realities (CREX)

Sector Update: Financial Stocks Advance Thursday Afternoon

MT Newswires Live

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

Applovin Corp Stock (APP) Moved Up by 3.05% on Aug 13: Key Drivers Unveiled

Citi Remains a Hold on Sight Sciences (SGHT)

Eco Wave Power Global (WAVE) Receives a Buy from Maxim Group

Citi Remains a Buy on Acumen Pharmaceuticals (ABOS)

AppLovin's Q2 Challenges Tied to Model Improvement Timing, RBC Says

MT Newswires Live

Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK4539/news?page=37"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":710.5842,"timestamp":1787687999999,"preClose":685.7458,"halted":0,"volume":327402228,"delay":0,"changeRate":0.036221,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":24.83844,"latestTime":"08-25 16:00:00 EDT","open":685.6775,"high":710.84143,"low":683.1322,"amount":10323480930.899076,"amplitude":0.040407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.436531,"peRate":156.391987,"turnoverRate":0.025401,"increases":84,"decrements":59,"flats":8,"marketCap":495359143396.625,"floatMarketCap":376108388528.9375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":710.84143,"amplitude":0.040407,"preClose":685.7458,"low":683.1322,"pbRate":"5.436531","latestPrice":710.5842,"volume":327402228,"delay":0,"open":685.6775,"prevYearClose":881.5255,"prevWeekClose":700.9769,"prevMonthClose":673.0273,"prevQuarterClose":742.922,"fiveDayClose":655.4622,"twentyDayClose":704.4272,"sixtyDayClose":779.4826,"secType":"PLATE","market":"US","turnoverRate":0.025401,"peRate":156.391987,"marketCap":495359143396.625,"floatMarketCap":376108388528.9375,"timestamp":1787687999999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":84,"down":59,"flat":11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:37,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659616261","title":"Press Release: dLocal Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616261?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"quarter of 2026, up 92% year-over-year compared to US$9.2 billion in the. second quarter of 2025 and up 26% compared to US$14.1 billion in the. first quarter of 2026. In constant currency, TPV growth for the period. -- Revenues amounted to US$399.7 million, up 56% year-over-year compared to. US$256.5 million in the second quarter of 2025 and up 19% compared to. US$335.9 million in the first quarter of 2026. In constant currency,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4106","BK4563","BK4227","DLO","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4568","BK4022","GDOC","BK4551","BK4535","BK4232","BNTX","BK4548","HYLG","BK4139","IND","MEDX","IVVD","IDNA","NVIB","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LFSC","CAR","TBXU","SYNB","PFS","CR","BK4230","BK4161","HYLG","LD","NVIB","BK4022","BK4585","BK4139","IDNA","GNOM","GDOC","MEDX","ORR","CRBU","IBB","BK4588","FBT","CNCR","BK4539","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162046","title":"Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162046","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162046?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Aug.  13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344905/0/en/mineralys-therapeutics-reports-inducement-award-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LCLG","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516475","title":"1stDibs Executives Present at Midwest IDEAS Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516475?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:00","pubTimestamp":1786651215,"startTime":"0","endTime":"0","summary":"1stDibs executives present at Midwest IDEAS Investor Conference1stDibs will present at the Midwest IDEAS Investor Conference in Chicago on Aug. 26 at 10:15 a.m. ET.CEO David Rosenblatt will appear alo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLChdld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4220","DIBS","BK4539","BK4122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659641571","title":"Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2659641571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659641571?lang=en_us&edition=fundamental","pubTime":"2026-08-14 03:35","pubTimestamp":1786649725,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Trevi Therapeutics, with a price target of $28.00. De...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-initiated-at-buy-on-clean-late-stage-execution-de-risked-ipf-cough-and-rcc-pipelines-and-solid-cash-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-initiated-at-buy-on-clean-late-stage-execution-de-risked-ipf-cough-and-rcc-pipelines-and-solid-cash-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RCC","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164651","title":"Sector Update: Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164651?lang=en_us&edition=fundamental","pubTime":"2026-08-14 03:17","pubTimestamp":1786648660,"startTime":"0","endTime":"0","summary":"Financial stocks were higher in late Thursday afternoon trading, with the NYSE Financial Index and the State Street Financial Select Sector SPDR ETF  each adding 0.5%.The Philadelphia Housing Index added 0.7%, and the State Street Real Estate Select Sector SPDR ETF  climbed 1.4%.Bitcoin  was fractionally lower at $63,401, and the yield for 10-year US Treasuries fell 4.1 basis points to 4.641%.In corporate news, Robinhood  plans to accelerate the pace of debuts for its publicly traded closed-end funds after its first two attempts to make private firms more accessible to its retail customers, Bloomberg reported, citing an interview with Robinhood CFO Shiv Verma. Robinhood shares were up 4.6%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DFII","CRPT","XLRE","CBOA","MAXI","BPI","CBOJ","HOOY","BK4585","BTC","CBTO","BITI","BITB","BITU","CBOY","HOOD","YBTC","HODU","EZBC","FINX","BITY","FBTC","BPAY","BTC.USD.CC","BTFX","MNRS","HOOX","BK4547","LU1861559042.SGD","IAI","BETE","BTRN","HOII","BITX","HOOI","LU1861558580.USD","XLF","BTCO","IBIT","HOYY","CBTJ","BTCZ","HOOW","HODL","ARKB","BK4539","BCCC","CBXO","SBIT","GBTC","BLCK","BAGY","CBXA","BTCC","BITO","BTCW","BTF","BTCL","CBOO","HOOG","CBXY","BFAP","HOOZ","BFJL","BK4127","BETH","ROBN","BRRR","BK4588","CBXJ","CBTA","XBTY","DEFI","CBTY","QBF","BTCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659161715","title":"Global-E CEO Amir Schlachet Sells 16,814 Shares for $713,890.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161715","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659161715?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:40","pubTimestamp":1786646403,"startTime":"0","endTime":"0","summary":"Global-e CEO Amir Schlachet sells 16,814 shares for $713,890.60Global-e Online CEO Amir Schlachet sold 16,814 ordinary shares on Aug. 12, 2026 at USD 42.41.Direct holdings stood at 3,948,286 ordinary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLcWRCc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Global-E CEO Amir Schlachet Sells 16,814 Shares for $713,890.60","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4122","BK4539","BK4220","BK4585","BK4588","GLBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659757161","title":"Obsidian Therapeutics Down over 21%, on Pace for Largest Percent Decrease Since October 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2659757161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659757161?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:37","pubTimestamp":1786646220,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics, Inc.  is currently at $22.00, down $6.00 or 21.43%--Would be lowest close since Aug. 3, 2026, when it closed at $18.99--On pace for largest percent decrease since Oct. 18, 2024, when it fell 21.85%--Currently down six of the past seven days--Currently down three consecutive days; down 37.14% over this period--Worst three day stretch since the three days ending Aug. 12, 2024, when it fell 45.7%--Up 40.85% month-to-date--Up 400% year-to-date--Down 99.38% from its all-time closing high of $3534.00 on March 2, 2020--Up 400% from 52 weeks ago , when it closed at $4.40--Down 37.14% from its 52-week closing high of $35.00 on Aug. 10, 2026--Up 587.5% from its 52-week closing low of $3.20 on Oct. 21, 2025--Traded as low as $17.05; lowest intraday level since Aug. 3, 2026, when it hit $16.00--Down 39.11% at today's intraday low; largest intraday percent decrease since Aug. 8, 2024, when it fell as much as 53.47%All data as of 2:34:16 PM ETSource: Dow Jones Market Data, Fac","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","OBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659617321","title":"Market Chatter: Robinhood Plans to Accelerate Debuts for Publicly Traded Closed-end Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2659617321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659617321?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:35","pubTimestamp":1786646114,"startTime":"0","endTime":"0","summary":"Robinhood Markets  plans to accelerate the pace of debuts for its publicly traded closed-end funds after its first two attempts to make private firms more accessible to its retail customers, Bloomberg reported Thursday, citing an interview with Robinhood chief financial officer Shiv Verma.Robinhood's first fund, with stakes in large private technology companies, debuted in March and is followed by a second fund set to begin trading Thursday, focusing on early stage firms coming out of the startup incubator, Y Combinator, according to the report.Robinhood Markets did not immediately respond to a request for comment by MT Newswires.Price: 98.48, Change: +3.57, Percent Change: +3.76","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HOOD","LU1861558580.USD","HOOX","HOOI","BK4539","HOYY","BPAY","HOOZ","HODU","ROBN","FINX","HOOY","HOII","BK4547","CRPT","IAI","BLCK","LU1861559042.SGD","BK4127","HOOW","HOOG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659648351","title":"Analysts Offer Insights on Technology Companies: Riskified (RSKD) and Creative Realities (CREX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659648351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659648351?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:30","pubTimestamp":1786645810,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Riskified (RSKD) and Creative Realities (CREX) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-riskified-rskd-and-creative-realities-crex-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-riskified-rskd-and-creative-realities-crex-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CREX","ARTY","TECS","BK4023","RSKD","BK4539","BK4009"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659169412","title":"Sector Update: Financial Stocks Advance Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2659169412","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659169412?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:29","pubTimestamp":1786642179,"startTime":"0","endTime":"0","summary":"Financial stocks were slightly higher in Thursday afternoon trading, with the NYSE Financial Index up 0.2% and the State Street Financial Select Sector SPDR ETF (XLF) fractionally higher.The Philadelp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","LU2360107671.USD","BITQ","ARX","BLCK","COIG","BK4173","CONL","XLRE","CRPT","LU1861558580.USD","FIAT","IBLC","BK4600","BK4588","LU1861217088.USD","BK4595","BK4596","CONY","XLF","LU1861559042.SGD","PSQH","DAPP","BK4585","BK4112","COIN","FDIG","COII","LU1861220207.SGD","COIW","BK4516","BK4554","BKCH","COIA","CONI","BK4077","COIO","COYY","BK4539","FINX","CONX","BK4535","ICOI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659691971","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659691971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659691971?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:20","pubTimestamp":1786641612,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-candel-therapeutics-cadl-lensar-lnsr-and-pyxis-oncology-pyxs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-candel-therapeutics-cadl-lensar-lnsr-and-pyxis-oncology-pyxs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4082","BK4588","XLV","BK4139","LABU","CADL","LU0128526141.USD","XBI","BK4581","BK4137","LNSR","HCSG","PYXS","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659716944","title":"Applovin Corp Stock (APP) Moved Up by 3.05% on Aug 13: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2659716944","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659716944?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:15","pubTimestamp":1786641329,"startTime":"0","endTime":"0","summary":"• AppLovin shares rebounded via dip-buying and short covering following a post-earnings pullback.\n• Management attributed AXON recommendation engine slowdowns to deployment timing rather than structural headwinds.\n• Technical indicators show an RSI of 26.600 and a Williams %R oversold condition.","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20251024/applovin-00fd0f57ca9840a2956911818360b64d.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/applovin-00fd0f57ca9840a2956911818360b64d.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262103219-market-movers-app-20260813","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2063271972.USD","IE00B19Z9P08.USD","LU1861215975.USD","BK4613","APPX","XDAT","LU2087625088.SGD","BK4539","BK4023","IE00B894F039.SGD","LU1861220033.SGD","LU2360107168.USD","BK4608","CLOD","IE00B19Z9Z06.USD","LU0056508442.USD","LU2250418816.HKD","LU0353189680.USD","LU2290526834.HKD","APP","LU0154236417.USD","IE00BZ9MQY76.HKD","LU1852331112.SGD","LU2360106780.USD","BK4009","LU0353189763.USD","BK4588","LU0097036916.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166417","title":"Citi Remains a Hold on Sight Sciences (SGHT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166417?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:15","pubTimestamp":1786637757,"startTime":"0","endTime":"0","summary":"Citi analyst Joanne Wuensch maintained a Hold rating on Sight Sciences today and set a price target of $8.00. According to TipRanks, Wuensch is a 4...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-remains-a-hold-on-sight-sciences-sght-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-remains-a-hold-on-sight-sciences-sght-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGHT","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659663701","title":"Eco Wave Power Global (WAVE) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2659663701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659663701?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:55","pubTimestamp":1786636531,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tate Sullivan from Maxim Group maintained a Buy rating on Eco Wave Power Global, with a price target of $15.00. Acc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eco-wave-power-global-wave-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eco-wave-power-global-wave-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4133","BK4539","WAVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659663411","title":"Citi Remains a Buy on Acumen Pharmaceuticals (ABOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659663411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659663411?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:46","pubTimestamp":1786635988,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham maintained a Buy rating on Acumen Pharmaceuticals today and set a price target of $4.00. Meacham covers the Healthcare s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-acumen-pharmaceuticals-abos-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-remains-a-buy-on-acumen-pharmaceuticals-abos-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","XLV","ABOS","LABU","XBI","BK4581","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659816575","title":"AppLovin's Q2 Challenges Tied to Model Improvement Timing, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659816575","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659816575?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:42","pubTimestamp":1786635763,"startTime":"0","endTime":"0","summary":"AppLovin's  Q2 challenges were largely related to the timing of a major \"model improvement\" rather than significant changes in demand or the competitive environment, RBC Capital Markets said in a note Thursday.The company's management said a \"sizable\" architectural model improvement was pushed from Q2 into Q3, with the company choosing not to accelerate the rollout at the expense of longer-term benefits. The improvement expands the parameters the model can ingest and is expected to allow AppLovin to make more complete use of its existing data.The investment firm said current Q3 guidance includes the benefit from the model improvement implemented early in the quarter but does not assume an \"incremental inflection.\"AppLovin's management also continues to see a long growth \"runway\" in gaming, though stronger growth over the next three to five years will require a larger contribution from consumer and e-commerce, according to the report.RBC maintained its outperform rating and $575 price t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2250418816.HKD","LU2290526834.HKD","LU2360107168.USD","BK4608","APP","LU0353189763.USD","BK4009","APPX","LU1861220033.SGD","BK4023","LU0097036916.USD","IE00B894F039.SGD","LU2063271972.USD","LU1852331112.SGD","LU0353189680.USD","BK4539","LU2087625088.SGD","CLOD","IE00BZ9MQY76.HKD","XDAT","LU0056508442.USD","LU0154236417.USD","LU1861215975.USD","LU2360106780.USD","IE00B19Z9P08.USD","BK4588","BK4585","IE00B19Z9Z06.USD","BK4613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165205","title":"Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165205?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:36","pubTimestamp":1786635368,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Dara Azar reiterated a Buy rating on Enliven Therapeutics today and set a price target of $82.00. According to TipRanks, Az...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4139","BK4007","BK4539","ELVN","SF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165487","title":"Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165487?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:33","pubTimestamp":1786635209,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated clinical strategy, RBC Capital Markets said in a note emailed Thursday.On the large B-cell lymphoma f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","LENZ","BK4539","ALLO","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":54,"pageCount":37,"totalSize":1072,"code":"91000000","status":"200"}]}}